Daiki Taniyama

The paper uses single-cell RNA sequencing to show heterogeneous SLFN11 expression in cancer cells, linking it to stress response and genome maintenance.

SCLC TumorMiner is a genomics platform that provides molecular classification, biomarker identification, and drug-response analysis for small cell lung cancer using integrated datasets from multiple institutions.

This study shows SLFN11 is highly expressed in multiple myeloma and normal plasma cells, and its nucleolar translocation in response to bortezomib correlates with drug resistance and therapeutic benefit.

The paper identifies that DUB inhibitors and RNF168-mediated ubiquitylation drive SLFN11 chromatin recruitment, particularly at promoters, and that this process is suppressed by TAK243.

This study identifies SLFN11 as a suppressor of the ALT telomere maintenance pathway, showing its re-expression reduces ALT activity in cancer cells.

This study identifies PRDX1's role in preventing oxidative damage to the nucleolar genome by maintaining rDNA transcription and ribosome biogenesis.

This study identifies TOP3A's role in ALT telomere maintenance, showing its enrichment at ALT telomeres and its impact on TERRA and TERF2 stability.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This paper identifies SEMA7A as a prognostic biomarker in adrenocortical carcinoma using transcriptome data from TCGA and NCI samples, showing its association with poor prognosis and specific signaling pathways.

The paper examines SLFN11 expression in B-cell development and lymphomas, finding it is epigenetically suppressed in germinal center B cells and that epigenetic modifiers enhance its expression, increasing sensitivity to cytosine arabinoside.